Welcome to the e-CCO Library!

DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mateos, B.(1)*;Gaite, A.(1);Rodríguez-Lago, I.(2);M. Marigorta, U.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP79: Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
Year: 2022
Source: ECCO'22
Authors: Sudhakar, P.(1);Salomon, B.(2);Verstockt, B.(1,3);Ungaro, R.(4);Aden, K.(5); D'Haens, G.(6);Komori, K.(7);Guay, H.(8);Silverberg, M.(9);Vermeire, S.(1,3);Halfvarson, J.(10); The COLLIBRI consortium
Created: Friday, 11 February 2022, 3:52 PM
DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. G. Feagan*1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3

Created: Friday, 22 February 2019, 9:41 AM
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series
Year: 2021
Source: ECCO'21 Virtual
Authors: Albshesh, A.(1);Eder, P.(2);Ribaldone , D.G.(3);Oldenburg, B.(4);De Boer, N.K.(5);Mantzaris, G.J.(6); Savarino, E.V.(7);Dragoni , G.(8);Weisshof, R.(9);Truyens, M.(10);Festa, S.(11);Maillard, M.H.(12);Capirchio , L.(13);Filip, R.(14);Kopylov, U.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Alric1, A. Amiot2, J. Kirchgesner3, X. Tréton4, M. Allez5, Y. Bouhnik4, L. Beaugerie3, F. Carbonnel1, A. Meyer1

Created: Thursday, 30 January 2020, 10:12 AM
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural network
Year: 2021
Source: ECCO'21 Virtual
Authors: SaraivaJr., M.(1);Ribeiro, T.(1);Afonso, J.(1);Cardoso, H.(1);Ferreira, J.(2);Andrade, P.(1);Parente, M.(2);Jorge, R.(2);Lopes, S.(1);Macedo, G.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP80: Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in Ulcerative Colitis (UC) (Phase 2b Vibrato study)
Year: 2022
Source: ECCO'22
Authors: Hassan-ZahraeePhD, M.(1);Ye, Z.(1);Xi, L.(1);Banerjee, A.(1);He, W.(1);Dushin, E.(1);Lee, J.(1);Altintas, E.(2);Romatowski, J.(3);Leszczyszyn, J.(4);Danese, S.(5);Sandborn, W.J.(6);Banfield, C.(1);Gale, J.(7);Peeva, E.(7);Vincent, M.(7);Hyde, C.(1);Longman, R.(8);Hung, K.E.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lawal, O.(1)*;Rodriguez-Sosa, A.(1);McDonnell, C.(1);Grant, L.(1);O'Brien, J.(2);Kel, A.(3);Dominik, A.(4);Stack, R.(5);Yochum, G.(6,7);Koltun, W.(6);Doherty, G.(5);Hussey, S.(8);
Created: Friday, 14 July 2023, 10:43 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Buisson*1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1

Created: Friday, 22 February 2019, 9:41 AM
DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.C. Dubinsky1, J.W. Chou2, C. Su3, W. Wang3, I. Modesto4, X. Guo3, S. Vermeire5

Created: Thursday, 30 January 2020, 10:12 AM
DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
Year: 2022
Source: ECCO'22
Authors: Verstockt, B.(1);Al Mahi, N.(2);Pivorunas, V.(3);Smaoui, N.(2);Guay, H.(3);Kennedy, N.A.(4);Hanauer, S.B.(5);Ferrante, M.(1);Panés, J.(6);Vermeire, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bossuyt, P.(1);Baert, D.(2);Baert, F.(3);Hoefkens, E.(1);Huys, I.(2);Lembrechts, N.(1);De Jonckere, E.(3);Dewint, P.(2);Pouillon, L.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lee, H.S.(1)*;Lee, Y.(1);Baek, J.(1);Kim, Y.(1);Park, S.(1);Jung, S.(1);Kim, K.K.(2);Hwang, S.W.(2);Lee, J.L.(3);Park, S.H.(2);Yang, S.K.(2);Han, B.(4);Song, K.(1);Yoon, Y.S.(3);Ye, B.D.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. L. Hamilton*1, P. P. De Cruz1,2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1

Created: Friday, 22 February 2019, 9:41 AM
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.M. Bloemendaal1, M. Becker1, P.J. Koelink1, J.D. van der Bilt2,3, W.A. Bemelman2, G.R.A.M. D’Haens4, C.J. Buskens2, M.E. Wildenberg1,4

Created: Thursday, 30 January 2020, 10:12 AM
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab
Year: 2022
Source: ECCO'22
Authors: Schreiber, S.W.(1);Cross, R.(2);Panaccione, R.(3);D'Haens, G.(4);Bossuyt, P.(5);Colombel, J.F.(6);Louis, E.(7);Dubinsky, M.(6);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Cheng, E.(8);Ferrante, M.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP82: Biological Treatment Cycles in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Noor, N.(1)*;Sousa, P.(2);Bettenworth, D.(3);Gomollon, F.(4);Lobaton, T.(5,6);Bossuyt, P.(7);Casanova, M.J.(8);Ding, N.(9);Dragoni, G.(10,11);Furfaro, F.(12);van Rheenen, P.(13);Chaparro, M.(8);Gisbert, J.(8);Louis, E.(14);Papamichael, K.(15);
Created: Friday, 14 July 2023, 10:43 AM
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Loftus- Jr, E.(1);Vermeire, S.(2);Feagan, B.(3);Yun, C.(4);Hsieh, J.(4);Liu, X.(4);Zhao, S.(4);Moerch, U.(5);Sandborn, W.J.(6);Hibi, T.(7)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Lo*1, I. Vind1, M. K. Vester-Andersen1,2, F. Bendtsen1, J. Burisch1

Created: Friday, 22 February 2019, 9:41 AM
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Creyns1,2, D. Gabriele3, C. Jonathan1,2, B. Verstockt2, G. Bislenghi4, F. Marc2,4, S. Vermeire2,4, G. Van Assche2,4, J. Ceuppens1, A. D’Hoore4, G. De Hertogh5, C. Breynaert1,6, Allergy and Clinical Immunology Research Group

Created: Thursday, 30 January 2020, 10:12 AM